{"id":50933,"date":"2022-11-16T12:02:57","date_gmt":"2022-11-16T11:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/"},"modified":"2022-11-16T12:02:57","modified_gmt":"2022-11-16T11:02:57","slug":"cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/","title":{"rendered":"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4330702\/cluster-headache-syndrome-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=sncscg&amp;utm_campaign=1776724+-+Cluster+Headache+Syndrome+Drug+Pipeline+Insight+Report+2022%3A+Comprehensive+Insights+About+5%2B+Companies+and+5%2B+Pipeline+Drugs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Cluster Headache Syndrome &#8211; Pipeline Insight, 2022&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis &#8220;Cluster Headache Syndrome- Pipeline Insight, 2022&#8221; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape.\n<\/p>\n<p>\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\nThe report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cluster Headache Syndrome pipeline landscape is provided which includes the disease overview and Cluster Headache Syndrome treatment guidelines. The assessment part of the report embraces, in depth Cluster Headache Syndrome commercial assessment and clinical assessment of the pipeline products under development.\n<\/p>\n<p>\nIn the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cluster Headache Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<p>\nThe companies and academics are working to assess challenges and seek opportunities that could influence Cluster Headache Syndrome R&amp;D. The therapies under development are focused on novel approaches to treat\/improve Cluster Headache Syndrome.\n<\/p>\n<p>\n<strong>Cluster Headache Syndrome Emerging Drugs Chapters<\/strong>\n<\/p>\n<p>\nThis segment of the Cluster Headache Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n<p>\n<strong>Cluster Headache Syndrome Emerging Drugs<\/strong>\n<\/p>\n<p>\n<strong>Eptinezumab: Lundbeck Seattle BioPharmaceuticals<\/strong>\n<\/p>\n<p>\nEptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. Currently, the drug is being developed in the Phase III stage of clinical trial evaluation for the treatment of Cluster Headache Syndromes.\n<\/p>\n<p>\n<strong>SYNP-101: Ceruvia Lifesciences<\/strong>\n<\/p>\n<p>\nSYNP-101 is a synthetic form of the naturally occurring compound, psilocybin, found in at least 200 species of mushrooms. Currently, the drug is being developed in the Phase I stage of clinical trial evaluation for the treatment of Cluster Headache Syndromes.\n<\/p>\n<p>\n<strong>Cluster Headache Syndrome: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the different Cluster Headache Syndrome drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n<p>\n<strong>Major Players in Cluster Headache Syndrome<\/strong>\n<\/p>\n<p>\nThere are approx. 5+ key companies which are developing the therapies for Cluster Headache Syndrome. The companies which have their Cluster Headache Syndrome drug candidates in the most advanced stage, i.e. phase III include, Lundbeck Seattle BioPharmaceuticals.\n<\/p>\n<p>\n<strong>Phases<\/strong>\n<\/p>\n<p>\n<strong>This report covers around 5+ products under different phases of clinical development like<\/strong>\n<\/p>\n<ul>\n<li>\nLate stage products (Phase III)\n<\/li>\n<li>\nMid-stage products (Phase II)\n<\/li>\n<li>\nEarly-stage product (Phase I) along with the details of\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<li>\nRoute of Administration\n<\/li>\n<\/ul>\n<p>\n<strong>Cluster Headache Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong>\n<\/p>\n<p>\n<strong>Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nIntra-articular\n<\/li>\n<li>\nIntraocular\n<\/li>\n<li>\nIntrathecal\n<\/li>\n<li>\nIntravenous\n<\/li>\n<li>\nOphthalmic\n<\/li>\n<li>\nOral\n<\/li>\n<li>\nParenteral\n<\/li>\n<li>\nSubcutaneous\n<\/li>\n<li>\nTopical\n<\/li>\n<li>\nTransdermal\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nOligonucleotide\n<\/li>\n<li>\nPeptide\n<\/li>\n<li>\nSmall molecule\n<\/li>\n<li>\nProduct Type\n<\/li>\n<\/ul>\n<p>\nDrugs have been categorized under various product types like Mono, Combination and Mono\/Combination.\n<\/p>\n<p>\n<strong>Cluster Headache Syndrome: Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cluster Headache Syndrome therapeutic drugs key players involved in developing key drugs.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cluster Headache Syndrome drugs.\n<\/p>\n<p>\nCluster Headache Syndrome Report Insights\n<\/p>\n<ul>\n<li>\nCluster Headache Syndrome Pipeline Analysis\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nImpact of Drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Cluster Headache Syndrome Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Questions<\/strong>\n<\/p>\n<p>\n<strong>Current Treatment Scenario and Emerging Therapies:<\/strong>\n<\/p>\n<ul>\n<li>\nHow many companies are developing Cluster Headache Syndrome drugs?\n<\/li>\n<li>\nHow many Cluster Headache Syndrome drugs are developed by each company?\n<\/li>\n<li>\nHow many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cluster Headache Syndrome?\n<\/li>\n<li>\nWhat are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cluster Headache Syndrome therapeutics?\n<\/li>\n<li>\nWhat are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?\n<\/li>\n<li>\nWhat are the clinical studies going on for Cluster Headache Syndrome and their status?\n<\/li>\n<li>\nWhat are the key designations that have been granted to the emerging drugs?\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nLundbeck Seattle BioPharmaceuticals\n<\/li>\n<li>\nCeruvia Lifesciences\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nEptinezumab\n<\/li>\n<li>\nSYNP-101\n<\/li>\n<li>\nNYPRG101\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4330702\/cluster-headache-syndrome-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=sncscg&amp;utm_campaign=1776724+-+Cluster+Headache+Syndrome+Drug+Pipeline+Insight+Report+2022%3A+Comprehensive+Insights+About+5%2B+Companies+and+5%2B+Pipeline+Drugs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/3d3gsu<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;&#x6f;:&#112;&#114;&#x65;&#x73;&#x73;&#64;r&#101;&#x73;&#x65;&#x61;rc&#104;&#97;&#x6e;&#x64;&#x6d;a&#114;&#107;&#x65;&#x74;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#101;&#x73;&#115;&#x40;&#114;&#x65;&#115;&#x65;&#97;&#x72;&#99;&#x68;&#97;&#x6e;&#100;&#x6d;&#97;&#x72;&#107;&#x65;&#116;&#x73;&#46;&#x63;&#111;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cluster Headache Syndrome &#8211; Pipeline Insight, 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;Cluster Headache Syndrome- Pipeline Insight, 2022&#8221; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50933","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cluster Headache Syndrome &#8211; Pipeline Insight, 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;Cluster Headache Syndrome- Pipeline Insight, 2022&#8221; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-16T11:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-11-16T11:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/\"},\"wordCount\":868,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005530\\\/en\\\/1639525\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/\",\"name\":\"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005530\\\/en\\\/1639525\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-11-16T11:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005530\\\/en\\\/1639525\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005530\\\/en\\\/1639525\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cluster Headache Syndrome &#8211; Pipeline Insight, 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;Cluster Headache Syndrome- Pipeline Insight, 2022&#8221; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-16T11:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs &#8211; ResearchAndMarkets.com","datePublished":"2022-11-16T11:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/"},"wordCount":868,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/","name":"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg","datePublished":"2022-11-16T11:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221116005530\/en\/1639525\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cluster-headache-syndrome-drug-pipeline-insight-report-2022-comprehensive-insights-about-5-companies-and-5-pipeline-drugs-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cluster Headache Syndrome Drug Pipeline Insight Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50933"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50933\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}